Apolipoprotein M Attenuates Anthracycline Cardiotoxicity and Lysosomal Injury

Research output: Contribution to journalJournal articleResearchpeer-review

Documents

  • Fulltext

    Final published version, 3.46 MB, PDF document

  • Zhen Guo
  • Carla Valenzuela Ripoll
  • Antonino Picataggi
  • David R. Rawnsley
  • Mualla Ozcan
  • Julio A. Chirinos
  • Ezhilarasi Chendamarai
  • Amanda Girardi
  • Terrence Riehl
  • Hosannah Evie
  • Ahmed Diab
  • Attila Kovacs
  • Krzysztof Hyrc
  • Xiucui Ma
  • Aarti Asnani
  • Swapnil V. Shewale
  • Marielle Scherrer-Crosbie
  • Lauren Ashley Cowart
  • John S. Parks
  • Lei Zhao
  • David Gordon
  • Francisco Ramirez-Valle
  • Kenneth B. Margulies
  • Thomas P. Cappola
  • Ankit A. Desai
  • Lauren N. Pedersen
  • Carmen Bergom
  • Nathan O. Stitziel
  • Michael P. Rettig
  • John F. DiPersio
  • Abhinav Diwan
  • Ali Javaheri

Apolipoprotein M (ApoM) binds sphingosine-1-phosphate (S1P) and is inversely associated with mortality in human heart failure (HF). Here, we show that anthracyclines such as doxorubicin (Dox) reduce circulating ApoM in mice and humans, that ApoM is inversely associated with mortality in patients with anthracycline-induced heart failure, and ApoM heterozygosity in mice increases Dox-induced mortality. In the setting of Dox stress, our studies suggest ApoM can help sustain myocardial autophagic flux in a post-transcriptional manner, attenuate Dox cardiotoxicity, and prevent lysosomal injury.

Original languageEnglish
JournalJACC: Basic to Translational Science
Volume8
Issue number3
Pages (from-to)340-355
ISSN2452-302X
DOIs
Publication statusPublished - 2023

Bibliographical note

Publisher Copyright:
© 2023 The Authors

    Research areas

  • anthracycline, apolipoprotein M, autophagy, cardiomyopathy, TFEB

ID: 340402091